Samchundang Pharm (000250) exhibited extreme volatility with a completely opposite stock price movement in a single day. Following news of receiving a U.S. FDA response letter related to oral semaglutide, the stock hit the upper limit the previous day, but on the second day, the 21st, it plunged more than 29%, effectively returning all of its gains.

According to the Korea Exchange (KRX) on the 21st, Samchundang Pharm closed the regular session at 167,800 won, down 71,200 won (29.79%) from the previous trading day. Selling pressure rapidly expanded after the early session, widening the decline. This was the exact opposite of the previous day's upper-limit performance, creating a so-called 'rollercoaster' market trend.

On the same day, while the KOSDAQ market saw modest gains, volatility was particularly pronounced in certain biotech sectors. The KOSDAQ index closed at 753.34, up 3.70 points (0.49%) from the previous trading day, maintaining a slightly bullish stance. However, despite the index's rise, some biotech stocks exhibited significantly expanded individual volatility.

The securities industry is focusing on the possibility that Samchundang Pharm's highly volatile market trend may continue for the time being. Samchundang Pharm had previously announced on the 20th that it received a U.S. FDA response letter regarding oral semaglutide.

[※ This article is not intended to solicit investment. The final judgment and responsibility for all investments lie with the investor.]